These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10917210)

  • 1. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.
    Dummer R; Bergh J; Karlsson Y; Horowitz JA; Mulder NH; Huinink DTB ; Burg G; Hofbauer G; Osanto S
    Cancer Gene Ther; 2000 Jul; 7(7):1069-76. PubMed ID: 10917210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma.
    Sauter ER; Takemoto R; Litwin S; Herlyn M
    Cancer Gene Ther; 2002 Oct; 9(10):807-12. PubMed ID: 12224020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.
    Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL
    Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
    Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
    Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer.
    Walther W; Siegel R; Kobelt D; Knösel T; Dietel M; Bembenek A; Aumann J; Schleef M; Baier R; Stein U; Schlag PM
    Clin Cancer Res; 2008 Nov; 14(22):7545-53. PubMed ID: 19010873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
    Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
    Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
    Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
    J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.
    Schuler M; Rochlitz C; Horowitz JA; Schlegel J; Perruchoud AP; Kommoss F; Bolliger CT; Kauczor HU; Dalquen P; Fritz MA; Swanson S; Herrmann R; Huber C
    Hum Gene Ther; 1998 Sep; 9(14):2075-82. PubMed ID: 9759934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
    Boulay JL; Perruchoud AP; Reuter J; Bolliger C; Herrmann R; Rochlitz C
    Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
    Cunningham CC; Chada S; Merritt JA; Tong A; Senzer N; Zhang Y; Mhashilkar A; Parker K; Vukelja S; Richards D; Hood J; Coffee K; Nemunaitis J
    Mol Ther; 2005 Jan; 11(1):149-59. PubMed ID: 15585416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
    Tong AW; Nemunaitis J; Su D; Zhang Y; Cunningham C; Senzer N; Netto G; Rich D; Mhashilkar A; Parker K; Coffee K; Ramesh R; Ekmekcioglu S; Grimm EA; van Wart Hood J; Merritt J; Chada S
    Mol Ther; 2005 Jan; 11(1):160-72. PubMed ID: 15585417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis.
    Gu J; Zhang L; Swisher SG; Liu J; Roth JA; Fang B
    Oncogene; 2004 Feb; 23(6):1300-7. PubMed ID: 14676844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
    Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells.
    Buttgereit P; Schakowski F; Märten A; Brand K; Renoth S; Ziske C; Schöttker B; Ebert O; Schroers R; Schmidt-Wolf IG
    Cancer Gene Ther; 2001 Jun; 8(6):430-9. PubMed ID: 11498763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice.
    Collinet P; Vereecque R; Sabban F; Vinatier D; Leblanc E; Narducci F; Querleu D; Quesnel B
    J Obstet Gynaecol Res; 2006 Oct; 32(5):449-53. PubMed ID: 16984510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
    Parker LP; Wolf JK; Price JE
    Ann Clin Lab Sci; 2000 Oct; 30(4):395-405. PubMed ID: 11045764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes.
    Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
    Gene Ther; 2006 Aug; 13(16):1235-43. PubMed ID: 16617300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.